Decoy Therapeutics Inc. - Common Stock (DCOY)

Recognition highlights the IMP³ACT™ platform and Designable Multi-Antivirals (D-MAVs), single drugs designed to work across many viruses

Lead pan-coronavirus program expected to file CTA/IND in 2H 2027Optimized lead candidate shows potential for once-weekly dosing in preclinical studiesCash on balance sheet of $8.1 million at September 30, 2026

NEW YORK, NY / ACCESS Newswire / October 1, 2026 / The Small Cap Showcase today will host eight micro and small cap public companies and a select audience of institutional and other qualified investors in New York City for a full day of company presentations, one on one meetings, and networking.